Related Experiment Video
Updated: Jun 14, 2025

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
Published on: January 20, 2023
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize
Anjali T Owens1, Milind Desai2, Matthew T Wheeler3
1University of Pennsylvania Perelman School of Medicine Philadelphia PA USA.
Insights
Mavacamten offers a new treatment for obstructive hypertrophic cardiomyopathy. An echocardiography-guided dosing strategy optimizes benefits and safety by monitoring left ventricular outflow tract gradient and ejection fraction.
Area of Science:
- Cardiology
- Pharmacology
- Medical Diagnostics
Background:
- Obstructive hypertrophic cardiomyopathy (oHCM) is a significant cardiovascular condition.
- Mavacamten is a novel cardiac myosin inhibitor approved for symptomatic NYHA class II-III oHCM.
- Individualized dosing is crucial for optimizing therapeutic outcomes and safety.
Purpose of the Study:
- To develop and validate an echocardiography-based, clinically guided dose-titration strategy for mavacamten.
- To optimize patient benefit in symptomatic obstructive hypertrophic cardiomyopathy.
- To minimize the risk of left ventricular ejection fraction reduction.
Main Methods:
- Utilized evidence-based rationale and clinical parameters for dosing.
- Employed echocardiography to monitor left ventricular (LV) outflow tract gradient and LV ejection fraction.
- Incorporated clinical trial data, modeling, and simulation analyses.
Main Results:
- The echocardiography-based strategy successfully identified individualized mavacamten doses for improved outcomes.
- Demonstrated improvements in LV outflow tract obstruction, functional capacity, and symptoms.
- Showcased a favorable safety profile, irrespective of CYP2C19 metabolizer status.
Conclusions:
- An echocardiography-guided dose-titration strategy effectively optimizes mavacamten therapy for oHCM.
- This approach balances therapeutic efficacy with the mitigation of adverse effects like reduced LV ejection fraction.
- The strategy accounts for patient-specific factors including CYP2C19 metabolism and potential drug interactions.
Abstract:
Mavacamten is the first and only cardiac myosin inhibitor approved in 5 continents for the treatment of adults with symptomatic New York Heart Association class II and III obstructive hypertrophic cardiomyopathy. An evidence-based rationale was used to develop individualized mavacamten dosing, guided by commonly used clinical parameters. Echocardiography is recommended as part of routine clinical assessment of patients with hypertrophic cardiomyopathy, and left ventricular (LV) outflow tract gradient and LV ejection fraction are parameters that can be readily assessed and monitored by echocardiography. Therefore, an echocardiography-based, clinically guided dose-titration strategy was developed to optimize patient benefit from mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy while minimizing the risk of LV ejection fraction reduction. Results from clinical trials paired with extensive modeling and simulation analyses support a dose-titration and monitoring strategy based on serial echocardiographic measures of Valsalva LV outflow tract gradient and LV ejection fraction. This dosing approach allows for the identification of the lowest individualized mavacamten dose and exposure required to provide improvements in LV outflow tract obstruction, functional capacity, and symptoms. Mavacamten is primarily metabolized by CYP2C19 (cytochrome P450 2C19), and CYP2C19 metabolizer phenotype has an effect on mavacamten exposure. Therefore, this approach has also been demonstrated to provide a favorable safety profile irrespective of patients' CYP2C19 metabolizer status. The dose-titration strategy includes additional considerations for the potential onset of systolic dysfunction in the context of intercurrent illness, and for the potential of drug-drug interactions with inhibitors and substrates of cytochrome P450 enzymes. This posology is reflected in the mavacamten US prescribing information.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: β-Blockers

